Dr. Geraghty serves as national or local principal investigator for a number of clinical trials of endovascular intervention, including the VIBRANT trial (percutaneous treatment of leg artery blockages for claudication) and the VIVA-1: XCELL Trial (percutaneous treatment of leg artery blockages for crirical limb ischemia).

He is also interested in the design, application, and outcomes of innovative, minimally invasive (endovascular) methods of treating leg artery blockages; the outcomes of endovascular repair of abdominal and thoracic aneurysms; and innovative methods to improve dialysis access.

Endovascular (minimally invasive) treatment of aortic aneurysms, aortoiliac occlusive disease, renovascular disease, carotid artery stenosis, lower extremity vascular disease, varicose veins, open surgical treatment for vascular diseases and hemodialysis access, Vein Center

Also, aortic dissection, arterial fibrodysplasia, atherosclerosis, Buerger's Disease, claudication, deep venous thrombosis, DVT, diabetic vascular disease, arterial dissection, arterial embolization, fibromuscular dysplasia, FMD, hardening of the arteries, intermittent claudication, intestinal ischemia, mesenteric ischemia, minimally invasive vascular therapy, pediatric vascular care, pediatric vascular surgery, peripheral vascular disease, renal artery disease, renovascular hypertension, thoracic aneurysm, thoracoabdominal aneurysm, thrombolytic therapy, vascular disease, venous insufficiency, interventional arterial procedures, interventional vascular lymphedema, diagnostic, arteriography, interventional arteriography, lymphedema

• Information for Patients